文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

贝美前列素不太可能失败，不会影响其他 IL-2 药物。

Bempeg Failure Unlikely to Affect Other IL2 Drugs.

出版信息

Cancer Discov. 2022 Jul 6;12(7):1604-1605. doi: 10.1158/2159-8290.CD-NB2022-0036.

DOI:10.1158/2159-8290.CD-NB2022-0036
PMID:35553619
Abstract

The engineered IL2 cytokine bempegaldesleukin fell flat in multiple late-stage clinical studies, prompting its developers-Nektar Therapeutics and Bristol Myers Squibb-to halt its clinical development. However, a pipeline of diverse IL2-based therapies may yet succeed.

摘要

工程化的白细胞介素 2 细胞因子 bempegaldesleukin 在多项后期临床试验中均以失败告终，促使其开发者——Nektar Therapeutics 和 Bristol Myers Squibb——停止了其临床开发。然而，多样化的基于白细胞介素 2 的治疗方法可能会成功。

相似文献

[1]
Bempeg Failure Unlikely to Affect Other IL2 Drugs.

Cancer Discov. 2022-7-6

[2]
Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice.

J Immunother Cancer. 2021-6

[3]
Combination of Bempegaldesleukin and Anti-CTLA-4 Prevents Metastatic Dissemination After Primary Resection or Radiotherapy in a Preclinical Model of Non-Small Cell Lung Cancer.

Front Oncol. 2021-4-15

[4]
Combining bempegaldesleukin (CD122-preferential IL-2 pathway agonist) and NKTR-262 (TLR7/8 agonist) improves systemic antitumor CD8 T cell cytotoxicity over BEMPEG+RT.

J Immunother Cancer. 2022-4

[5]
28th Annual JPMorgan Healthcare Conference--Exelixis and Nektar Therapeutics.

IDrugs. 2010-3

[6]
Malignant plasma cells are sensitive to LAK cell lysis: pre-clinical and clinical studies of interleukin 2 in the treatment of multiple myeloma.

Br J Haematol. 1990-8

[7]
Interleukin-2 in neuroblastoma: clinical perspectives based on biological studies.

Cancer Biother Radiopharm. 1996-10

[8]
Fusion cytokine IL-2-GMCSF enhances anticancer immune responses through promoting cell-cell interactions.

J Transl Med. 2016-2-5

[9]
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study.

J Immunother Cancer. 2022-4

[10]
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors.

Cancer Discov. 2019-4-15

引用本文的文献

[1]
Bispecific antibody for lung cancer: mechanisms and clinical insights.

Front Immunol. 2025-5-29

[2]
Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy.

Onco Targets Ther. 2024-8-29

[3]
Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends.

Exp Mol Med. 2024-9

[4]
MB2033, an anti-PD-L1 × IL-2 variant fusion protein, demonstrates robust anti-tumor efficacy with minimal peripheral toxicity.

Cancer Immunol Immunother. 2024-6-4

[5]
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities.

Signal Transduct Target Ther. 2024-5-22

[6]
Engineering cytokines for cancer immunotherapy: a systematic review.

Front Immunol. 2023

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索